Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07382583 · ClinicalTrials.gov registry record
Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the Primary Prevention of Endometrial Cancer
A clinical trial of Endometrial Cancer and Prevention, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 270
- Enrollment target
- 2
- Study locations
NCT07382583: Recruiting study of Endometrial Cancer and Prevention, sponsored by M.D. Anderson Cancer Center.
NCT07382583 is a study of Endometrial Cancer and Prevention that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 270 participants, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (48% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07382583, a study of Endometrial Cancer and Prevention, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 270 participants
- Enrollment target
- 2
- Study locations
Study Summary
To develop an educational tool to help patients and healthcare professionals make informed decisions about endometrial cancer and available prevention options for it (such as the use of a levonorgestrel-releasing intrauterine system \[LNG-IUS\]).
Conditions Studied
Interventions
- OTHER Survey using a questionnaire
Study Locations (2)
Texas
- The Harris Health System (LBJ) - Houston
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2026-02-12 |
| Est. Completion | 2030-02-01 |
What NCT07382583 shows while recruiting
NCT07382583 is an observational study that tracks outcomes without assigning an intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (48% lower).
The record links to 4 conditions, with Endometrial Cancer appearing as the primary indexed condition, and to 1 intervention - of which Survey using a questionnaire is the first listed.
NCT07382583 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07382583 about?
NCT07382583 is a clinical study titled "Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the Primary Prevention of Endometrial Cancer". To develop an educational tool to help patients and healthcare professionals make informed decisions about endometrial cancer and available prevention options for it (such as the use of a levonorgestrel-releasing intrauterine system \[LNG-IUS\]).
What is the current status of trial NCT07382583?
This trial is currently recruiting. The enrollment target is 270 participants. The study started on 2026-02-12. Estimated completion is 2030-02-01.
What conditions does trial NCT07382583 study?
This clinical trial studies the following conditions: Endometrial Cancer, Prevention, Levonorgestrel, Intrauterine Systems.
What interventions are being tested in trial NCT07382583?
The interventions under investigation include: Survey using a questionnaire (OTHER).
Who is sponsoring clinical trial NCT07382583?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07382583 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07382583's enrollment target sits among peer trials
270 50th of 181 higher than 131 of 181 other Endometrial Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
The Better, Harder, Faster, Stronger Study
RECRUITING
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- NCT04372485 · 270 participants · NA
Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents
- NCT04528446 · 270 participants
The Impact of Glomerular Disorders on Bone Quality and Strength
- NCT05215327 · 270 participants · Phase 2
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI